FIELD: biotechnology.
SUBSTANCE: disclosed are biparatopic antibody or its antigen-binding fragment, which specifically bind human folate receptor 1 (FRα), and a method for production thereof, an isolated nucleic acid molecule encoding a biparatopic antibody or an antigen-binding fragment thereof, an isolated vector for expressing the biparatopic antibody or an antigen-binding fragment thereof, host cell, pharmaceutical composition for treating FRα-expressing cancer. There are also presented immunoconjugates which specifically bind human folate receptor 1 (FRα), and their use for treating cancer, a pharmaceutical composition for treating FRα-expressing cancer, containing an immunoconjugate.
EFFECT: invention is used to treat disorders such as cancer by administering a biparatopic antibody which specifically binds to FRα and modulates FRα activity.
41 cl, 19 dwg, 23 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| METHODS FOR DETECTING FOLATE RECEPTOR 1 IN PATIENT SAMPLE | 2018 |
|
RU2759410C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
